{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-025530","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2025-08-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.494345+00:00","generated_at":"2026-05-17T09:57:26.837574+00:00","sec_items":["1.01","5.03","3.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Evofem Biosciences amends merger agreement with Aditxt, exchanges $1.573M notes for Series G-1 Preferred Stock","bullets":["Sixth Amendment to A&R Merger Agreement updated definitions to include Series G-1 Preferred, set dissenting share cap at 5,932,818 common shares and 202 preferred shares.","Exchanged $1.573M aggregate principal of senior secured convertible notes for 1,573 Series G-1 Preferred shares (stated value $1,000/share, conversion price $0.0154).","Series G-1 Preferred carries voting rights (as-converted), monthly dividends in stock or PIK, and trigger-event conversion at alternative prices with 25% premium.","Amendment requires waivers from all Series E-1 Preferred holders on price adjustment and other provisions, and updated exchange agreement for convertible noteholders.","Merger with Aditxt remains pending; proxy statement to be filed for shareholder vote."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-025530","json":"https://secwatch.observer/filing/0001641172-25-025530.json","markdown":"https://secwatch.observer/filing/0001641172-25-025530.md","text":"https://secwatch.observer/filing/0001641172-25-025530.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000164117225025530/0001641172-25-025530-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000164117225025530/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T09:57:26.837574+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b04b012c81871724a2ff3ce9922762eea3ba420b","claim":"Evofem Biosciences, Inc.: Filed Certificate of Designations creating Series G-1 Preferred Stock, amending Articles of Incorporation (effective 2025-08-22).","evidence_excerpt":"On August 22, 2025 the Company filed the Certificate of Designations creating the Series G-1 Preferred Stock.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000164117225025530/0001641172-25-025530-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-08-22"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}